Article Abstract

Is there a place for Ramucirumab after Sorafenib in patients with advanced HCC?

Authors: Yeo Jeong So, Sophia Frentzas, Eva Segelov


Hepatocellular carcinoma (HCC) is the sixth most common incident and the fourth most common cause of cancer death worldwide. It is strongly associated with chronic Hepatitis B and C infection and excess alcohol intake (1), making treatment of patients with HCC complicated, with the almost uniform presence of concurrent cirrhosis and varying degrees of liver failure, which often fluctuates over time.